An interventional study of Deep learning based reconstruction of T2-TSE sequence in Prostate Cancer and Multiparametric MRI, sponsored by University Hospital, Bonn. Completed at 1 site in Germany. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-19.
Sponsored by University Hospital, Bonn · Not applicable, Interventional, and Diagnostic
The aim of this study was therefore to investigate a new unrolled DL super resolution reconstruction of an initially low-resolution Cartesian T2 turbo spin echo sequence (T2 TSE) and compare it qualitatively and quantitatively to standard high-resolution Cartesian and non-Cartesian T2 TSE sequences in the setting of prostate mpMRI with particular interest in image sharpness, conspicuity of lesions and acquisition time. Furthermore, the investigators assessed the agreement of assigned PI-RADS scores between deep learning super resolution and standard sequences.
Prostate cancer has been among the most prevalent cancer types in men for years, being responsible for 7.8% of all newly diagnosed cases in 2020, holding the 2th place right after lung cancer. Early and non-invasive diagnostics was improved vastly by multiparametric MRI (mpMRI) of the prostate, detecting clinically significant prostate cancer and forming the baseline for guided biopsy of the prostate, while it can prevent unnecessary biopsies in patients with elevated prostate specific antigen, but no visible lesions. With an aging population fast, efficient and highly qualitative MRI scans are needed to satisfy this increasing demand. Deep learning image reconstruction has become increasingly important solving these tasks to produce highly qualitative images while drastically reducing acquisition time.
Standard acquisition protocols of prostate mpMRI include T2-weighted, diffusion-weighted and dynamically contrast-enhanced sequences to allow for the classification of prostatic lesions according to the Prostate Imaging Reporting \& Data System (PI-RADS). While the assignment of the PI-RADS score in the peripheral zone of the prostate is mainly determined by the diffusion weighted imaging, the T2-weighted-sequences are mainly responsible for the assessment of the transitional zone. Furthermore, thorough assessment of the prostate necessitates acquisition of T2-weighted sequences in axial and sagittal planes, thus extending acquisition time of MRI protocols. Different approaches have been proposed to accelerate and improve the image acquisition, ranging from the implementation of shortened protocols to the improvement of diffusion weighted sequences or using compressed sensing for the reconstruction of non-Cartesian T2-weighted-sequences. Besides these methods that rely on traditional acquisition and reconstruction methods, deep learning (DL) image reconstruction has become increasingly important solving these tasks to produce highly qualitative images while drastically reducing acquisition time.
Despite that, reliable DL-methods for the process of image acquisition and reconstruction of prostate mpMRI itself are sparse. While first approaches for DL denoising has been established, effectively replacing the conventional wavelet function, the remainder of the iterative reconstruction cycle is unaffected and the impact on diagnostic performance of the PI-RADS score remains unclear. Recently developed super resolution deep learning networks are promising to overcome this limitation. First results for DL denoising in different applications, e.g. in musculoskeletal MRI already show good results, leading to significant acceleration of acquisition time while maintaining high image quality. However, the application of these denoising DL-networks in combination with more advanced super resolution networks in prostate mpMRI hasn't been evaluated yet.
In this prospective study, between August and November 2022, participants with suspicion for prostate cancer underwent prostate MRI with standard high-resolution Cartesian T2 (T2C) and non-Cartesian T2 (T2NC) sequences. Additionally, a low-resolution Cartesian T2 TSE (T2SR) with DL denoising and super resolution reconstruction was acquired. Artifacts, image sharpness, lesion conspicuity, capsule delineation, overall image quality and diagnostic confidence were rated on a 5-point-Likert-Scale with being non-diagnostic and 5 being excellent. Apparent signal-to-noise ratio (aSNR), contrast-to-noise ratio (aCNR) and edge rise distance (ERD) were calculated. Friedman test and One-way ANOVA were used for group comparisons. Regarding agreement of PI-RADS scores were compared with Cohen's Kappa.
6,367 studies on the registry are indexed under Prostatic Neoplasms; 1,397 are open to participants now.
This study's enrollment of 109 is above the median of 58 across 4,821 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →University Hospital, Bonn is the lead sponsor of 154 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants undergo multiparametric MRI of the prostate with inclusion of standard cartesian T2-TSE and non-cartesian T2-weighted sequences, as well as a newly developed deep learning enhanced T2-TSE sequence. All patients in this study undergo the same imaging protocol.
Device: Deep learning based reconstruction of T2-TSE sequence
A newly developed deep-learning based reconstruction of a primarily low-resolved T2-TSE sequence is included in the imaging protocol for evaluation of prostate cancer.
Qualitative assessment of image quality (Artifacts, image sharpness, lesion conspicuity, capsule delineation, overall image quality and diagnostic confidence)
Artifacts, image sharpness, lesion conspicuity, capsule delineation, overall image quality and diagnostic confidence were rated on a 5-point-Likert-Scale with 1 being non-diagnostic and 5 being excellent. Friedman test was used for significance testing with p\<0.05 considered as indicative of a significant difference.
Time frame: 4 months
Acquisition time
Measurement of acquisition time of T2-weighted sequences
Time frame: 4 months
Degree of agreement on PI-RADS ratings
To assess the PI-RADS score, all MRIs were read blinded by a radiologist with 11 years expertise at two different time points in random order. The MRI sequences for PI-RADS assessment included either T2NC (reference standard at our institution) or T2SR as the T2-weighted sequence in the reading protocol. The remainder of sequences were the same (axial T1-weighted TSE pre and post contrast administration, axial dynamically contrast enhanced T1, sagittal T2 TSE and axial diffusion weighted sequences with apparent diffusion coefficient map). Cohen's Kappa was used for correlation of readings with inclusion of either T2SR or T2NC.
Time frame: 4 months
Quantitative assessment of image quality (apparent signal-to-noise and contrast-to-noise ratio)
Apparent signal-to-noise ratio (aSNR: signal intensity of peripheral zone/standard deviation of muscle) and contrast-to-noise ratio (aCNR: signal intensity of peripheral zone - signal intensity of muscle)/standard deviation of muscle) was calculated to quantify the image sharpness. One-way ANOVA was used for significance testing with p\<0.05 considered as indicative of a significant difference.
Time frame: 4 months
Quantitative assessment of image quality (edge rise distance)
Edge rise distance (ERD) was calculated to quantify the image sharpness. The ERD was determined as a measure of image sharpness. For this purpose, a line was drawn perpendicularly crossing the dorsal border of the prostate capsule. The edge rise distance was then determined as the distance (in mm) between the 10% and 90% signal intensity levels relative to the low and high signal intensity areas. One-way ANOVA was used for significance testing with p\<0.05 considered as indicative of a significant difference.
Time frame: 4 months
Plan to share: No
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bonn